Clinical Trial Update: A Multi-center Study of Low-dose Decitabine for the Treatment of Immune Thrombocytopenia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating low-dose decitabine for immune thrombocytopenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Decitabine (Decitabine)

Snippet

Sponsor: Shandong University | Conditions: Immune Thrombocytopenia | Phase 2 | Status: COMPLETED